AustralianSuper Pty Ltd Sells 36,769 Shares of Hologic, Inc. $HOLX

AustralianSuper Pty Ltd lowered its position in shares of Hologic, Inc. (NASDAQ:HOLX) by 30.9% in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 82,361 shares of the medical equipment provider’s stock after selling 36,769 shares during the period. AustralianSuper Pty Ltd’s holdings in Hologic were worth $5,559,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in HOLX. Root Financial Partners LLC bought a new stake in shares of Hologic in the 3rd quarter worth $27,000. Chung Wu Investment Group LLC purchased a new stake in shares of Hologic during the second quarter valued at $26,000. Caitong International Asset Management Co. Ltd boosted its position in shares of Hologic by 193.6% during the second quarter. Caitong International Asset Management Co. Ltd now owns 414 shares of the medical equipment provider’s stock valued at $27,000 after buying an additional 273 shares during the last quarter. SJS Investment Consulting Inc. increased its holdings in Hologic by 341.5% in the 3rd quarter. SJS Investment Consulting Inc. now owns 468 shares of the medical equipment provider’s stock worth $32,000 after buying an additional 362 shares in the last quarter. Finally, Loomis Sayles & Co. L P purchased a new position in Hologic in the 2nd quarter worth about $33,000. 94.73% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

HOLX has been the topic of a number of recent analyst reports. Needham & Company LLC reaffirmed a “hold” rating on shares of Hologic in a report on Tuesday, November 4th. BNP Paribas Exane cut shares of Hologic from a “strong-buy” rating to a “hold” rating and set a $79.00 target price on the stock. in a report on Friday, November 21st. Argus downgraded shares of Hologic from a “buy” rating to a “hold” rating in a research report on Monday, January 12th. Evercore ISI cut Hologic from an “outperform” rating to an “in-line” rating and lowered their price target for the company from $79.00 to $78.00 in a report on Monday, January 5th. Finally, Leerink Partners raised their price target on Hologic from $70.00 to $78.00 and gave the stock a “market perform” rating in a research note on Tuesday, October 21st. Three research analysts have rated the stock with a Buy rating and thirteen have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, Hologic presently has a consensus rating of “Hold” and a consensus price target of $79.31.

Hologic Trading Down 0.2%

Shares of HOLX stock opened at $74.98 on Friday. The company has a debt-to-equity ratio of 0.50, a current ratio of 3.75 and a quick ratio of 3.06. The company has a market cap of $16.74 billion, a price-to-earnings ratio of 30.23, a PEG ratio of 2.13 and a beta of 0.69. Hologic, Inc. has a 1 year low of $51.90 and a 1 year high of $75.36. The firm has a fifty day moving average price of $74.88 and a 200-day moving average price of $70.78.

Hologic (NASDAQ:HOLX) last released its earnings results on Thursday, January 29th. The medical equipment provider reported $1.04 earnings per share for the quarter, missing the consensus estimate of $1.09 by ($0.05). Hologic had a net margin of 13.80% and a return on equity of 20.13%. The company had revenue of $1.05 billion for the quarter, compared to analysts’ expectations of $1.07 billion. As a group, equities analysts predict that Hologic, Inc. will post 4.28 earnings per share for the current year.

Hologic Profile

Hologic, Inc (NASDAQ: HOLX) is a global medical technology company specializing in women’s health. Headquartered in Marlborough, Massachusetts, the company develops and manufactures diagnostic products, imaging systems and surgical solutions designed to detect, diagnose and treat diseases with a primary focus on breast and skeletal health, gynecological conditions and molecular diagnostics. Its product portfolio includes digital mammography systems, 3D mammography solutions, bone densitometry equipment and molecular assays for infectious disease and oncology applications.

Since its founding in 1985, Hologic has grown through both internal innovation and strategic acquisitions.